C4X Discovery Holdings PLC: Tax3 platform has identified 3 genetic sub-types in Parkinson’s Disease

Software developed by Oxford e-Research Centre in collaboration with C4X Discovery Limited and the Mathematical Institute should reduce the time taken to develop new drugs for complex disorders such as Parkinson’s disease.

Obtaining regulatory approval for a new drug is not only costly, but can take up to 10 years. The process is tricky and fails around 90% of the time. The success rate can be dramatically increased, even doubled using genetic evidence, however, it is extremely difficult to understand the genetic basis of complex disorders such as Parkinson’s disease and diabetes. In Parkinson’s, for example, 70% of the ‘genetic load’ – the proportion that an illness is due to genetic rather than environmental factors – is unexplained. Conventional analysis generates limited information and insights, often identifying just one significant gene variable. The onset of complex disorders is thought to rely on the interaction of many variables, something not examined by these traditional methods.

 

C4X Discovery Holdings PLC (LON:C4XD) is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    C4X Discovery Holdings Plc

    More articles like this

    C4X Discovery Holdings Plc

    Alderley Park opens access to NMR facility for biotech firms

    Manchester Science Partnership’s Alderley Park campus has launched an open-access, nuclear magnetic resonance (NMR) facility. Typically, the only way for companies to access NMR spectroscopy equipment has been through academia, however the Cheshire bioscience campus has

    C4X Discovery Holdings Plc

    C4X Discovery Enters New Strategic Collaboration with Evotec

    Commenting on the strategic collaboration, Clive Dix, CEO of C4X Discovery, commented: “We are delighted to expand on our successful relationship with Evotec through this alliance that is designed to support us in achieving our vision